Log In
BCIQ
Print this Print this
 

Elocta, Eloctate, efmoroctocog alfa (rFVIIIFc) (BIIB031)

Also known as: Long-lasting rFACTOR VIII

  Manage Alerts
Collapse Summary General Information
Company Biogen Inc.
DescriptionLong-acting recombinant fusion protein consisting of the Fc domain of human gG1 attached to Factor VIII
Molecular Target Factor VIII
Mechanism of ActionFactor VIII replacement
Therapeutic ModalityBiologic: Fusion protein
Latest Stage of DevelopmentMarketed
Standard IndicationHemophilia
Indication DetailsTreat and prevent bleeding in hemophilia A patients; Treat hemophilia A; Treat severe hemophilia A
Regulatory Designation U.S. - Orphan Drug (Treat hemophilia A);
U.S. - Undisclosed Review (Treat hemophilia A);
EU - Orphan Drug (Treat hemophilia A);
Switzerland - Orphan Drug (Treat and prevent bleeding in hemophilia A patients);
Switzerland - Orphan Drug (Treat hemophilia A)
PartnerSwedish Orphan Biovitrum AB;
UCB Group

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

02/03/2014

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today